Dendritic cell therapy is a personalized cancer vaccine made from each patient's own immune cells. German labs collect monocytes from the blood, mature them into dendritic cells, expose them to the patient's own tumour markers, and infuse them back — where they trigger T-cells to attack the cancer. It's used for breast, brain, pancreatic, and ovarian cancers, often alongside checkpoint inhibitors.
Reply in 4 hours · Plan and quote in 2 days · 100% confidential
Dendritic Cell Therapy (DCT) is a cutting-edge, highly personalized form of cancer immunotherapy that empowers your own immune system to fight cancer more effectively. Instead of using external chemicals or radiation, this therapy works by retraining the body’s natural defenses to recognize and destroy cancer cells—just like they would a virus or bacteria.
Here’s how it works: a small amount of your blood is drawn to isolate monocytes, which are then matured in a special lab setting into dendritic cells—the most powerful messengers of the immune system. These cells are then exposed to your tumor’s unique antigens, giving them a “blueprint” of what to attack. Once reintroduced into your body, these primed dendritic cells stimulate cytotoxic T-cells—your immune army—to seek out and eliminate cancer cells with remarkable precision.
Whether it’s being used for metastatic breast cancer, glioblastoma, pancreatic tumors, or recurrent ovarian cancer, DCT is gaining traction in Germany as a promising, non-toxic option for patients who may have exhausted traditional therapies. German cancer institutes are now integrating DCT into comprehensive treatment plans that focus not just on survival—but on improving quality of life, energy, and long-term immunity.
From Dendritic Cell Therapy for Metastatic Breast Cancer in Germany to Glioblastoma, this targeted immune intervention is becoming a cornerstone of integrative oncology in German cancer centers.
Dendritic Cell Therapy (DCT) is a special treatment that uses your own blood to help your body fight cancer. Doctors take a small sample of your blood, prepare special cells in a lab to recognize your cancer, and then put them back into your body. These cells help your immune system find and attack the cancer more effectively. It’s a gentle and natural approach with fewer side effects, and it’s being used in Germany for hard-to-treat cancers like breast, brain, ovarian, and pancreatic cancer. Many patients try this when other treatments haven’t worked and are looking for a safer, hopeful option.
Dendritic cells are the sentinels of the immune system. In DCT:
DCT may be a good option for people who:
In top cancer hospitals across Germany, DCT is being used for both common and rare cancers when other options are limited or have stopped working.
Dendritic Cell Therapy (DCT) is best suited for patients who are dealing with advanced, recurrent, or difficult-to-treat cancers, such as metastatic breast cancer, glioblastoma (brain tumors), stage 4 pancreatic cancer, ovarian cancer, prostate cancer, or rare aggressive tumors. It’s also a good option for people who:
Germany has emerged as a global leader in individualized immunotherapy, particularly Dendritic Cell Therapy (DCT) for advanced or treatment-resistant cancers. Renowned cancer centers and private clinics across Germany offer cutting-edge DCT programs integrated with genomic profiling, targeted therapies, and follow-up immunomonitoring. These centers emphasize personalized protocols, experienced oncologists, and high international patient care standards. Many hospitals offer multilingual support, tailored accommodation, and post-therapy monitoring to improve patient outcomes and quality of life.
| Hospital/Clinic Name | City | Highlights | Special Focus Areas |
| HUMAN CLINIC – Prof. Dr. Frank Gansauge | Baden-Baden | Pioneer in dendritic cell vaccines, integrative cancer therapies | Pancreatic, Liver, Breast, Prostate, Brain |
| Hallwang Private Oncology Clinic | Freudenstadt | Comprehensive immunotherapy, personalized cancer vaccines | Breast, Ovarian, Lung, Melanoma, Glioblastoma |
| IOZK Immun-Onkologisches Zentrum Köln | Cologne | DCT with virotherapy, virus-modified immune cells, CAR-T strategies | Brain Tumors, Glioblastoma, Prostate, Colorectal |
| Medias Klinikum | Burghausen | Advanced-stage cancer protocols, IPT, oncothermia + DCT | Sarcomas, Pancreas, Head & Neck, Breast |
| Frontier Medical Germany | Munich & Berlin | International coordination, immune cell therapy with genomics support | Prostate, Breast, Lung, Colorectal |
| University Hospital Heidelberg (NCT) | Heidelberg | Research-oriented, academic DCT integration with checkpoint inhibitors | Pancreas, Brain, GI, Hematological |
The Dendritic Cell Therapy cost in Germany typically ranges from €18,000 to €45,000, depending on the type of cancer, the stage of the disease, and the complexity of the personalized vaccine protocol. A complete DCT program usually involves leukapheresis (white cell extraction), antigen loading, dendritic cell maturation, and multiple infusions—often integrated with other supportive therapies like hyperthermia, low-dose chemotherapy, or virotherapy. Top private clinics such as HUMAN CLINIC (Prof. Dr. Frank Gansauge), IOZK Cologne, and Hallwang Oncology Clinic offer tailored treatment plans and post-therapy immune monitoring, adding to the overall cost. Some centers offer packages inclusive of diagnostics, inpatient care, nutrition, and immunological follow-up.
| Procedure | Cost (EUR) |
| Initial Consultation & Tumor Panel | €1,000–€1,500 |
| Leukapheresis + Cell Culture | €4,000–€6,000 |
| Antigen Loading + DCT Cycle | €5,000–€7,500 per cycle |
| Full Package (3–6 Cycles) | €15,000–€35,000 |
Cancer Round Services act as a trusted bridge between international patients and top German immuno-oncology centers. Their role includes:
These services ensure patients are treated at verified centers, avoid miscommunication, and receive individualized attention from world-renowned experts, such as Prof. Dr. Frank Gansauge, who are otherwise difficult to access directly.
Prof. Dr. med. Frank Gansauge — Leader in Dendritic Cell Therapy (LANEX‑DC®)
Affiliation & Role:
| Category | Highlights |
| Immuno‑oncology Specialist | Trained surgeon turned immunologist with >22 years dedicated to dendritic cell therapy, combining oncology and cellular immunology |
| Treatment Innovation | Introduced fresh (non-frozen) dendritic cell vaccination, preserving maximal cellular potency and shorter protocols per cycle |
| Clinical Research Leadership | Conducted and published retrospective studies on >200 pancreatic and colorectal cancer patients, demonstrating median survival extension up to 17.5 months with repeated cycles |
| High Global Volume & Experience | Over 2,500 LANEX‑DC® treatments performed at his facility; one of the few centers globally focusing solely on advanced dendritic cell immunotherapy |
| Strong Academic Credentials | Author of more than 160 scientific publications, winner of awards including the Fred Stephans Award and Merckle Research Award; multiple visiting professorships internationally |
| EU-GMP Certified Laboratory | Operates an EU-GMP compliant clean room for vaccine production with stringent quality control and fresh cell protocols |
| Personalized & Patient-Centered Approach | Integrates immunotherapy with other standard treatments; highly engaging in patient education, comfort, and holistic care |
| Multilingual & International Patient Access | Frequently treats international patients, offers support in English, and navigates logistic and regulatory aspects smoothly |
Prof. Dr. med. Frank Gansauge is a pioneering immunotherapy specialist with decades of surgical and research experience in cancer care. His LANEX‑DC® dendritic cell therapy center in Neu‑Ulm stands out for its high patient volume, innovative fresh-cell protocols, and excellent tolerability. With strong academic output and global reputation, he remains a top choice for international patients seeking advanced dendritic cell treatment in Germany.
While individual results vary, studies from German cancer centers show that DCT can help:
DCT is not a cure, but in the right patients, it can slow down disease progression and give the immune system a better chance to control the cancer.
| Cancer Type | Ideal Candidate Profile | Prognosis / DFS Benefit |
| Metastatic Breast Cancer | Failed chemo; hormone receptor positive or triple-negative; looking for low-toxicity option | DFS extended by 6–10 months in responders; improved energy and symptom control |
| Stage 4 Pancreatic Cancer | Not eligible for surgery or full-dose chemo; locally advanced or metastatic disease | Some patients show 3–6 months extra survival; slows down progression with fewer side effects |
| Prostate Cancer (Advanced) | Castration-resistant cases; slow-growing but progressing disease | Stable disease seen in select patients; may delay need for chemo |
| Ovarian Cancer (Recurrent) | Post-surgery relapse; platinum-resistant; low immunity | Prolonged DFS in selected cases; better tolerance than second-line chemo |
| Glioblastoma / Brain Tumors | Post-surgery or post-radiotherapy cases; limited systemic options | 12-month survival rate improved in some trials; slows recurrence |
| Head & Neck Cancers | HPV-negative or recurrent; post-radiotherapy cases | Enhanced local immune response, reduced recurrence seen in German studies |
| Rare / Aggressive Tumors | Soft tissue sarcoma, neuroendocrine tumors, etc.; lack of standard treatment | Experimental but promising outcomes when combined with supportive therapies |
| After Chemotherapy or Surgery | Patients in remission but at high risk of recurrence | May offer immune surveillance benefit; helps the body recognize and destroy new cancer cells |
Good to Know: Patients in Germany typically undergo 3–6 DCT cycles spaced over weeks or months. The best outcomes are often seen when DCT is started early after relapse or used alongside other therapies.
While DCT is generally well-tolerated, contraindications may include:
Possible complications (rare):
Germany’s integrative oncology units ensure post-DCT care includes:
German centers coordinate with cancer rounds team comprising:
Together, they ensure precise candidate selection, cell processing, and real-time response tracking for international and domestic patients.
| City | Hospital/Institute | Specialty |
| Berlin | Berlin Immunotherapy Institute | Stage 4 solid tumors, recurrent ovarian and breast ca |
| Heidelberg | Heidelberg University Hospital (NCT) | Glioblastoma, advanced pancreatic cancer |
| Munich | Medias Klinikum | Head & neck, prostate, glioma |
| Frankfurt | Frankfurt Oncology & Immunotherapy Center | DCT + checkpoint inhibitors combo |
| Hamburg | UKE – University Medical Center Hamburg-Eppendorf | Breast, ovarian, and pediatric tumor DCT |
For International Patients
Outcomes are enhanced when DCT is paired with low-dose chemotherapy, checkpoint inhibitors, or hyperthermia.
For international patients exploring advanced, highly personalized immunotherapy options abroad, Dendritic Cell Therapy (DCT) in Germany represents a leading-edge solution. Germany’s commitment to innovative cancer research and advanced immune-oncology attracts individuals from the UK, US, Canada, Ireland, Saudi Arabia, Holland, the broader Middle East, and globally. If you’re an international patient seeking alternative or complementary cancer treatments and navigating complex medical landscapes, Cancer Rounds is your dedicated specialized medical facilitator, immune-oncology expert, and international patient coordinator, simplifying access to Germany’s pioneering Dendritic Cell Therapy clinics and specialized services, particularly in research-driven cities like Frankfurt, Cologne, and Berlin.
German medical institutions are globally recognized for their cutting-edge approach to immune-oncology, seamlessly integrating advanced cell culture facilities, personalized treatment protocols, and rigorous scientific oversight. Patients choose Germany for compelling reasons when considering Dendritic Cell Therapy (DCT) medical tourism:
At Cancer Rounds, we understand the specific complexities involved in accessing specialized, innovative treatments like Dendritic Cell Therapy – from identifying the right clinics and navigating complex protocols to managing logistics. We act as your essential conduit, directly connecting you with Germany’s top dendritic cell therapy clinics and leading immune-oncology specialists in key centers like Frankfurt, Cologne, and Berlin. We are leaders in international patient services for advanced cancer therapies.
If you are from the UK exploring advanced, non-conventional cancer treatments or require an expert assessment for dendritic cell therapy beyond what’s available domestically, Cancer Rounds provides direct pathways to German innovation. Similarly, patients from the US looking for pioneering European immune-oncology approaches or Canadians seeking alternative cancer therapies can leverage our services for consultations and access to specialized DCT programs in Germany’s advanced facilities. We ensure you receive thorough medical reviews from esteemed overseas specialists.
We recognize the unique considerations for patients from the Middle East and Saudi Arabia when pursuing cutting-edge dendritic cell therapy in Europe. Cancer Rounds meticulously streamlines your journey, arranging swift access to leading German immune-oncology specialists in cities such as Frankfurt and Berlin, facilitating expert consultations for DCT suitability, and linking you with personalized immune treatments. We are your dedicated ally in securing high-quality innovative cancer care in Germany without the typical logistical complexities.
Whether you are from Ireland seeking next-generation immunotherapies for cancer, or from Holland and other international locations exploring the potential of dendritic cell therapy, Cancer Rounds ensures a seamless and efficient process. We simplify access to specialized DCT programs and personalized treatment planning in Germany’s leading immune-oncology centers, empowering you to focus entirely on your health and potential recovery.
Cancer Rounds offers meticulous, end-to-end support tailored for patients accessing highly specialized treatments. Our services encompass all logistical intricacies, including medical record translation, visa assistance, travel arrangements, specialized accommodation, and crucial language assistance throughout your medical journey in Germany. We meticulously manage these details so you can concentrate solely on your health and treatment, making international medical travel for immunotherapy stress-free. Our extensive network guarantees you receive a bespoke treatment strategy, leveraging Germany’s advanced medical capabilities, precisely tailored to your individual needs as an international cancer patient.
Do not let geographical distance or administrative complexities impede your access to pioneering Dendritic Cell Therapy in Germany. Let Cancer Rounds be your trusted guide to receiving timely, comprehensive, and advanced immune-oncology care in Germany’s celebrated medical centers. Contact us for Germany cancer treatment cost information and to understand more about how to get innovative treatment in Germany for cancer.
Dendritic Cell Therapy (DCT) is an advanced personalized immunotherapy that uses a patient’s own immune cells to recognize and attack cancer. In this procedure, dendritic cells are harvested, matured in a lab, loaded with tumor antigens, and reintroduced to stimulate a targeted immune response. This helps the body recognize and destroy cancer cells more effectively. It’s especially promising for patients with advanced-stage or relapsed cancers.
German immunotherapy centers have reported positive outcomes using DCT for:
It is also used as a recurrence-prevention strategy post-surgery or chemotherapy in certain cancers.
Patients who are:
DCT is particularly valuable for patients who want a non-toxic, organ-preserving cancer treatment.
Some of the leading DCT centers include:
These centers offer world-class facilities, personalized protocols, and integration with hyperthermia, virotherapy, or low-dose chemo.
The indicative cost of DCT in Germany ranges from €18,000 to €45,000. It depends on:
The full DCT cycle usually takes 2 to 4 weeks, including:
Some patients may return home in between or extend the stay for integrated therapies.
Dendritic Cell Therapy is generally well-tolerated. Minor side effects may include:
These symptoms are usually short-lived and indicate immune activation. Compared to chemotherapy, DCT has minimal toxicity and no organ damage.
DCT is not a miracle cure, but it has shown:
Success often depends on early initiation, tumor biology, and whether it’s used as part of a multimodal treatment plan.
Yes. In Germany, multimodal protocols are popular:
This synergistic approach may increase the immune response and target cancer more effectively while preserving patient strength.
Cancer Rounds offers:
Published By
.webp){kind=logo}
Global Patient Care, Redefined
The CancerRounds Medical Content Team specialises in creating accurate, clear and patient-focused healthcare content. Our content is written by medically trained writers, medically reviewed, and based on reputable medical sources to support informed healthcare decisions.
Get expert guidance instantly
Share a few details and our medical team gets back to you within 4 hours with the next steps.
Tell us what you are facing and our medical team will guide you to the right doctors, hospitals and treatment.
Free Review, No Commitment
Free assessment with no pressure to proceed.
Trusted by 100,000+ Patients
Across 125+ countries worldwide
500+ Top Partner Hospitals
Globally accredited medical facilities
5000+ Expert Specialists
Senior doctors across major specialties.
Making quality healthcare accessible to patients worldwide
Everything you need to know about choosing the right hospital, doctor and treatment plan.
